AllSci News
AbbVie's atogepant meets primary endpoint in Phase III menstrual migraine trial
Atogepant (Qulipta/Aquipta) met the primary endpoint and all eight ranked secondary endpoints in the Phase III LUNA trial evaluating preventive treatment of...
ViaNautis expands into spinal cord injury with SCI Ventures backing for polyNaut platform
Cambridge, UK-based ViaNautis Bio has secured investment from SCI Ventures to expand its non-viral genetic medicine delivery platform into chronic spinal...
NodThera rebrands as Rezera as ruvonoflast meets Phase II endpoint, eyes Phase III in PAD
Ruvonoflast (NT-0796), an oral NLRP3 inflammasome inhibitor developed by Boston-based Rezera Inc. (formerly NodThera), met its primary endpoint in the...
Mindera Health partners with UPenn to investigate quinacrine mechanism in lupus
Mindera Health is collaborating with University of Pennsylvania researchers to investigate why quinacrine helps some patients with cutaneous lupus—and...
Seismic launches global Phase III trial of istaroxime in cardiogenic shock
Durham, North Carolina-based Seismic Pharmaceuticals has launched a global Phase III trial of istaroxime in cardiogenic shock, a life-threatening condition...
UpDoc receives up to USD 9.2m from ARPA-H for autonomous heart failure AI system
Palo Alto-based UpDoc has been selected as a lead performer in the Advanced Research Projects Agency for Health (ARPA-H) ADVOCATE program, receiving an...
Cytonics crowdfunds USD 4.8m to advance A2M biologic into Phase Ib/IIa osteoarthritis study
Jupiter, Florida-based Cytonics Corporation has completed a USD 4.8 million gross-proceeds financing campaign, bringing total capital raised to USD 47...
Insightec spinout Lotus Neuro launches brain drug delivery platform
Lotus Neuro, a clinical-stage biotechnology company spun out of focused ultrasound specialist Insightec, launched publicly with a platform designed to...
Disc Medicine’s DISC-3405 reduces phlebotomy needs in Phase II polycythemia vera trial
Massachusetts-based Disc Medicine (Nasdaq: IRON) released Phase II data showing that DISC-3405, an anti-TMPRSS6 monoclonal antibody, sharply reduced...
Insilico’s rentosertib becomes first AI-discovered drug to enter Phase III
Insilico Medicine (HKEX: 3696) has dosed the first patient in GENESIS-IPF-3, the Phase III trial of rentosertib (ISM001-055 / INS018\055) in idiopathic...
Tempus wins USD 9.5m in ARPA-H funding to develop autonomous cardiology AI
Tempus AI (Nasdaq: TEM) secured up to USD 9.5 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop and clinically validate an...
Roche moves Enspryng toward first approved MOGAD therapy
Roche (SIX: RO; OTCQX: RHHBY) announced a US FDA Priority Review award for a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab),...
Bayer’s Hyrnuo joins Boehringer’s Hernexeos in first-line HER2-mutant NSCLC
The US FDA has granted accelerated approval to Hyrnuo (sevabertinib) for the first-line treatment of adults with locally advanced or metastatic non-squamous...
McGill and Mount Sinai researchers identify PRMT7 as suppressor of CD8+ T cell expansion
A protein arginine methyltransferase acts as a previously unrecognized suppressor of cytotoxic T cell proliferation, offering a potential new target for...
BioNTech ends autogene cevumeran Phase II after OS imbalance favors control
The BNT122-01 Phase II trial of autogene cevumeran in resected colorectal cancer has been terminated after an independent data safety monitoring board...
The AllSci Brief
Free, systematic R&D and deal news. Daily.